Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

Roivant Sciences (ROIV)

Nasdaq Health Care Biotechnology S&P MidCap 400
$38.88
+2.26 (+6.17%)
Close of Nov 06, 2026 · end-of-day data
Source: Roivant Sciences's 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 02, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD
Fiscal yearFY2021FY2022FY2023FY2024FY2025FY2026
Revenue$23.80M$55.29M$31.53M$32.71M$29.05M$8.26M
Research & development$236.63M$483.04M$454.06M$439.91M$550.41M$681.81M
Selling, general & admin—$775.03M$600.51M$687.44M——
Operating income-$1.07B-$1.35B-$906.76M$4.50B-$1.00B-$515.07M
Interest expense$2.81M$7.04M$27.97M$34.78M——
Pre-tax income-$898.55M-$923.75M-$884.99M$4.57B-$681.59M-$264.58M
Income tax$1.69M$369.00K$4.08M$21.50M$48.17M$133.33M
Net income-$809.23M-$845.26M-$1.01B$4.35B-$171.98M-$299.77M
EBITDA—-$1.35B-$887.91M$4.52B-$989.22M-$511.72M
EPS (basic)$-1.28$-1.26$-1.42$5.55$-0.24$-0.43
EPS (diluted)$-1.28$-1.26$-1.42$5.23$-0.24$-0.54
Diluted shares630.05M669.75M712.79M831.05M725.40M693.86M
Operating margin-4500.5%-2444.8%-2875.9%13746.9%-3453.3%-6235.7%
Net margin-3400.9%-1528.9%-3200.2%13294.2%-592.0%-3629.2%

Balance sheet

fiscal years · USD
Fiscal yearFY2021FY2022FY2023FY2024FY2025FY2026
Cash & equivalents$2.06B$2.06B$1.68B$6.49B$2.72B$1.42B
Short-term investments———$0$2.17B$2.87B
Receivables$11.22M$3.88M$30.38M$3.99M——
Inventory—$0$2.76M$35.25M——
Total current assets$2.19B$2.15B$1.80B$6.73B$5.00B$5.17B
Total assets$2.59B$2.59B$2.39B$7.22B$5.44B$5.71B
Total current liabilities$218.96M$184.37M$272.45M$266.76M$149.41M$281.24M
Short-term debt$0$0$40.72M$12.00M——
Long-term debt$170.28M$210.03M$375.51M$430.59M——
Total debt$170.28M$210.03M$416.24M$442.59M——
Total liabilities$527.69M$523.70M$782.02M$773.95M$249.74M$416.27M
Shareholders' equity$1.80B$1.66B$1.16B$5.97B$4.69B$4.53B

Cash flow

fiscal years · USD
Fiscal yearFY2021FY2022FY2023FY2024FY2025FY2026
Operating cash flow-$552.14M-$677.73M-$843.39M-$765.27M-$839.45M-$750.35M
Capital expenditures$5.81M$17.44M$12.69M$1.38M$4.60M$8.21M
Free cash flow-$557.94M-$695.16M-$856.08M-$766.65M-$844.05M-$758.56M
Investing cash flow-$31.70M$303.30M-$44.27M$5.20B-$1.77B-$682.33M
Financing cash flow$456.26M$306.79M$499.46M$419.36M-$1.22B$134.24M
Share buybacks——$0$0$1.29B—
Stock-based compensation$84.96M$564.96M$217.78M$199.63M$289.03M$346.17M
Depreciation & amortization—$5.93M$18.86M$22.04M$14.07M$3.35M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.